BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 18541514)

  • 1. [New molecular targets in pancreatic cancer].
    Torrisani J; Bournet B; Cordelier P; Buscail L
    Bull Cancer; 2008 May; 95(5):503-12. PubMed ID: 18541514
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Molecular pathways of pancreatic carcinogenesis].
    Torrisani J; Buscail L
    Ann Pathol; 2002 Oct; 22(5):349-55. PubMed ID: 12483152
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Recent advances in gene change of pancreatic cancer].
    Wang YY; Cui QC
    Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2004 Feb; 26(1):79-82. PubMed ID: 15052782
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Advance in the biology of pancreatic of cancer].
    Buscail L; Bournet B; Dufresne M; Torrisani J; Cordelier P
    Bull Cancer; 2015 Jun; 102(6 Suppl 1):S53-61. PubMed ID: 26118878
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparative analysis of K-ras point mutation, telomerase activity, and p53 overexpression in pancreatic tumours.
    Uemura K; Hiyama E; Murakami Y; Kanehiro T; Ohge H; Sueda T; Yokoyama T
    Oncol Rep; 2003; 10(2):277-83. PubMed ID: 12579258
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Genetics of pancreatic cancer: recent advances in molecular diagnosis].
    Hayashi N; Egami H; Ogawa M
    Nihon Geka Gakkai Zasshi; 2002 Jun; 103(6):476-81. PubMed ID: 12094699
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Molecular biology of pancreatic cancer; oncogenes, tumour suppressor genes, growth factors, and their receptors from a clinical perspective.
    Sakorafas GH; Tsiotou AG; Tsiotos GG
    Cancer Treat Rev; 2000 Feb; 26(1):29-52. PubMed ID: 10660490
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Molecular diagnosis of pancreatic cancer.
    Inoue S; Tezel E; Nakao A
    Hepatogastroenterology; 2001; 48(40):933-8. PubMed ID: 11490843
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [General rules for the study of pancreatic cancer by molecular biological aspect].
    Omata M; Tada M
    Nihon Geka Gakkai Zasshi; 2000 Feb; 101(2):233-6. PubMed ID: 10734643
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pancreatic cancer: a plea for good and comprehensive morphological studies.
    Algül H; Schmid RM
    Eur J Gastroenterol Hepatol; 2008 Aug; 20(8):713-5. PubMed ID: 18617774
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The mutant K-ras oncogene causes pancreatic periductal lymphocytic infiltration and gastric mucous neck cell hyperplasia in transgenic mice.
    Brembeck FH; Schreiber FS; Deramaudt TB; Craig L; Rhoades B; Swain G; Grippo P; Stoffers DA; Silberg DG; Rustgi AK
    Cancer Res; 2003 May; 63(9):2005-9. PubMed ID: 12727809
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Genomic instability at both the base pair level and the chromosomal level is detectable in earliest PanIN lesions in tissues of chronic pancreatitis.
    Baumgart M; Werther M; Bockholt A; Scheurer M; Rüschoff J; Dietmaier W; Ghadimi BM; Heinmöller E
    Pancreas; 2010 Oct; 39(7):1093-103. PubMed ID: 20531246
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Molecular prognostic markers in pancreatic cancer.
    Ghaneh P; Kawesha A; Evans JD; Neoptolemos JP
    J Hepatobiliary Pancreat Surg; 2002; 9(1):1-11. PubMed ID: 12021893
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Kras(G12D) and Smad4/Dpc4 haploinsufficiency cooperate to induce mucinous cystic neoplasms and invasive adenocarcinoma of the pancreas.
    Izeradjene K; Combs C; Best M; Gopinathan A; Wagner A; Grady WM; Deng CX; Hruban RH; Adsay NV; Tuveson DA; Hingorani SR
    Cancer Cell; 2007 Mar; 11(3):229-43. PubMed ID: 17349581
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inactivation of Smad4 accelerates Kras(G12D)-mediated pancreatic neoplasia.
    Kojima K; Vickers SM; Adsay NV; Jhala NC; Kim HG; Schoeb TR; Grizzle WE; Klug CA
    Cancer Res; 2007 Sep; 67(17):8121-30. PubMed ID: 17804724
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Differential genetic pathway of duct and acinar carcinomas of the pancreas].
    Tsutsumi M
    Gan To Kagaku Ryoho; 2005 May; 32(5):593-8. PubMed ID: 15918556
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Molecular pathogenesis of pancreatic adenocarcinoma: potential clinical implications.
    Talar-Wojnarowska R; Malecka-Panas E
    Med Sci Monit; 2006 Sep; 12(9):RA186-93. PubMed ID: 16940943
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mutation status of K-ras, p53 and allelic losses at 9p and 18q are not prognostic markers in patients with pancreatic cancer.
    Salek C; Minarikova P; Benesova L; Nosek V; Strnad R; Zavoral M; Minarik M
    Anticancer Res; 2009 May; 29(5):1803-10. PubMed ID: 19443408
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Major molecular markers in pancreatic ductal adenocarcinoma and their roles in screening, diagnosis, prognosis, and treatment.
    Singh P; Srinivasan R; Wig JD
    Pancreas; 2011 Jul; 40(5):644-52. PubMed ID: 21673535
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Genetic diagnosis of pancreatic cancer.
    Mizumoto K; Tanaka M
    J Hepatobiliary Pancreat Surg; 2002; 9(1):39-44. PubMed ID: 12021896
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.